Biomatrica Inc., a San Diego-based developer of ambient temperature biostability technology, completed $5 million in private financing.
Biomatrica developed SampleMatrix technology, which has pioneered recent innovations in ambient storage of biological samples, from purified DNA, RNA and proteins to complex systems such as tissue, cell lines, biopsies and whole blood. The company's products serve such customers as those in the molecular diagnostics, forensics, biomedical research (academic, government and industry), and biobanks.
"With the new funding, we can accelerate the launch of new technologies and products that will stabilize diagnostic assays at ambient temperature," said Judy Muller-Cohn, Ph.D., CEO and co-founder of Biomatrica. "The growth of next generation sample-to-answer diagnostic tests is rapidly emerging, and Biomatrica can offer custom solutions to companies in the molecular diagnostic space."
Biomatrica is also funded by Defense Advanced Research Project Agency (DARPA) for basic technology development to solve some of the hardest biostability problems under the Diagnostics on Demand (DxOD) program. Within this program, Biomatrica is combining its proprietary biostability technology with the most advanced next generation diagnostics technology, enabling their applications on a global scale without cold chain requirements.
"Biomatrica's novel chemical stabilization technology offers significant advantages in costs and performance for ambient temperature assays," said Rolf Muller, Ph.D., CSO and co-founder of Biomatrica. "Funds raised in this round of financing will enable us to strengthen our research initiatives, increase manufacturing capabilities and improve company infrastructure."